C-C motif chemokine receptor 2 inhibition reduces liver fibrosis by restoring the immune cell landscape
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The accumulation of extracellular matrix (ECM) proteins in the liver leads to liver fibrosis and end-stage liver cirrhosis.C-C motif chemokine receptor 2 (CCR2) is an attractive target for treating liver fibrosis.However, limited investigations have been conducted to explore the mechanism by which CCR2 inhibition reduces ECM accumulation and liver fibrosis, which is the focus of this study.Liver injury and liver fibrosis were induced by carbon tetrachloride (CCl4) in wild-type mice and Ccr2 knockout (Ccr2 -/-) mice.CCR2 was upregulated in murine and human fibrotic livers.Pharmacological CCR2 inhibition with cenicriviroc (CVC) reduced ECM accumulation and liver fibrosis in prevention and treatment administration.In single-cell RNA sequencing (scRNA-seq), CVC was demonstrated to alleviate liver fibrosis by restoring the macrophage and neutrophil landscape.CVC administration and CCR2 deletion can also inhibit the hepatic accumulation of inflammatory FSCN1 + macrophages and HERC6 + neutrophils.Pathway analysis indicated that the STAT1, NFκB, and ERK signaling pathways might be involved in the antifibrotic effects of CVC.Consistently, Ccr2 knockout decreased phosphorylated STAT1, NFκB, and ERK in the liver.In vitro, CVC could transcriptionally suppress crucial profibrotic genes (Xaf1, Slfn4, Slfn8, Ifi213, and Il1β) in macrophages by inactivating the STAT1/NFκB/ERK signaling pathways.In conclusion, this study depicts a novel mechanism by which CVC alleviates ECM accumulation in liver fibrosis by restoring the immune cell landscape.CVC can inhibit profibrotic gene transcription via inactivating the CCR2-STAT1/NFκB/ERK signaling pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · cited 2×
“Chronic inflammation induced by immune cells activates HSCs, leads to ECM deposition, reconstructs hepatic lobules, and eventually promotes liver fibrosis.[5, 13, 32, 33] Although many clinical practices and basic research have been performed, effective antifibrotic drugs remain deficient.”
BackgroundResolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice
Petrasek, J., Bala, S., Csak, T., Lippai, D., Kodys, K., Menashy, V., Barrieau, M., Min, S.-Y., Kurt-Jones, E. A., & Szabo, G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60777 · Cited by 735 · cited 1×
“However, except for Il1β, which has well-known functions during liver fibrosis,[40, 41] Xaf1, Slfn4, Slfn8, and Ifi213 are profibrotic genes with unknown functions.”
BackgroundFriedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671 · cited 2×
“Recent studies have demonstrated that pharmacological inhibition of CCR2 by CVC decreases hepatic steatosis and fibrosis [15, 25, 26] Furthermore, CCR2 inhibition by CVC can improve insulin resistance and steatohepatitis in NASH patients.[27, 28] Whether CVC can also improve liver fibrosis in other models remains unkn…”
BackgroundPradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613 · cited 2×
“[19, 20, 34] Activated CCR2 causes M1-polarized macrophage recruitment and ECMproducing HSC activation, ultimately leading to liver fibrosis.[12, 21, 35] Consistently, we verified the upregulation of CCR2 in murine and human fibrotic livers.”
BackgroundOn-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver
Theurl, I., Hilgendorf, I., Nairz, M., Tymoszuk, P., Haschka, D., Asshoff, M., He, S., Gerhardt, L. M. S., Holderried, T. A. W., Seifert, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4146 · Cited by 412
Baeck, C., Wei, X., Bartneck, M., Fech, V., Heymann, F., Gassler, N., Hittatiya, K., Eulberg, D., Luedde, T., Trautwein, C., et al. (2014) · Hepatology · doi:10.1002/hep.26783 · Cited by 270 · cited 1×
“[12] Consistently, CCR2+ MDMs have been verified to participate in liver fibrosis and angiogenesis.[12, 21-23] Thus, CCR2 is supposed to be an attractive target for the clinical treatment of liver cirrhosis.”
BackgroundHilscher, M. B., Sehrawat, T., Arab, J. P., Zeng, Z., Gao, J., Liu, M., Kostallari, E., Gao, Y., Simonetto, D. A., Yaqoob, U., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.03.013 · Cited by 240 · cited 3×
“[6-11] In the injured liver, liver sinusoidal endothelial cells (LSECs) rapidly respond to injuries by recruiting other immune cells to the liver, eventually constructing a proinflammatory and profibrotic ECM deposition microenvironment.[8, 11-13] Of these recruited immune cells, macrophages and neutrophils are the pr…”
BackgroundSelf-citationMacrophages contribute to the pathogenesis of sclerosing cholangitis in mice
Guicciardi, M. E., Trussoni, C. E., Krishnan, A., Bronk, S. F., Lorenzo Pisarello, M. J., O'Hara, S. P., Splinter, P. L., Gao, Y., Vig, P., Revzin, A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.018 · Cited by 183
Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis
Liu, M., Cao, S., He, L., Gao, J., Arab, J. P., Cui, H., Xuan, W., Gao, Y., Sehrawat, T. S., Hamdan, F. H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24843-w · Cited by 120
Self-citation
Cited by
Guillot, A., & Tacke, F. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000491 · Cited by 45
Beyond M1/M2: The role of reactive oxygen species in liver fibrosis and immune modulation
Lu, H., Huang, J., Wang, Y.-C., Casals, E., Casals, G., & Zeng, M. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103933 · Cited by 19
“In parallel, M2-secreted CCL2 recruits additional CCR2 + monocytes from the circulation, thereby sustaining an inflammatory loop that fuels both immune cell infiltration and HSC activation [34,84, 106].”
Novel regulators of hepatic macrophages in liver fibrosis
Tang, X., Bai, M., Du, X., Wang, H., Liu, M., Fu, X., Zhang, H., Liang, S., & Wang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1705503 · Cited by 12
Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
Aquino, J. B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1792423 · Cited by 1
Metadata
- Authors
- Guo, Y., Zhao, C., Dai, W., Wang, B., Lai, E., Xiao, Y., Tang, C., Huang, Z., & Gao, J.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2023
- Volume
- 19
- Issue
- 8
- Pages
- 2572-2587
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W4377564137
- Cited by
- 30
- References
- 16
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: C-C motif chemokine receptor 2 inhibition reduces liver fibrosis by restoring the immune cell landscape. https://app.cochat.ai/papers/10.7150/ijbs.83530
- The paper
- Guo, Y., Zhao, C., Dai, W., Wang, B., Lai, E., Xiao, Y., Tang, C., Huang, Z., & Gao, J. (2023). C-C motif chemokine receptor 2 inhibition reduces liver fibrosis by restoring the immune cell landscape. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.83530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.